Pier 88 Investment Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Pier 88 Investment Partners’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$254K	Sell	69,200 -14,500	-17%	-$48.3K	0.06%	84
2026 Q1	$257K	Sell	83,700 -13,440	-14%	-$51.9K	0.07%	101
2025 Q4	$397K	Sell	97,140 -21,420	-18%	-$106K	0.09%	99
2025 Q3	$579K	Buy	118,560 +44,050	+59%	+$231K	0.11%	86
2025 Q2	$377K	Sell	74,510 -20,280	-21%	-$99.6K	0.07%	94
2025 Q1	$501K	Sell	94,790 -66,940	-41%	-$488K	0.1%	86
2024 Q4	$1.09M	Buy	161,730 +27,820	+21%	+$187K	0.22%	50
2024 Q3	$882K	Buy	133,910 +109,210	+442%	+$783K	0.19%	61
2024 Q2	$185K	Buy	+24,700	New	+$215K	0.04%	92

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Pier 88 Investment Partners's RXRX Position: Q2 2026 in Review

Pier 88 Investment Partners reduced its Recursion Pharmaceuticals (RXRX) stake by 17% in Q2 2026, selling an estimated $48.3K and leaving 69,200 shares worth $254K. The position accounts for 0.06% of the portfolio, ranked #84.

Pier 88 Investment Partners first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.09M in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Pier 88 Investment Partners held 69,200 shares of Recursion Pharmaceuticals worth $254K as of Q2 2026.
Pier 88 Investment Partners sold 14,500 Recursion Pharmaceuticals shares in Q2 2026, an estimated $48.3K.
Recursion Pharmaceuticals made up 0.06% of Pier 88 Investment Partners's portfolio in Q2 2026, its #84 holding.
Pier 88 Investment Partners first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Pier 88 Investment Partners's Recursion Pharmaceuticals position peaked at $1.09M in Q4 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Pier 88 Investment Partners's 13F filing for Q2 2026, filed 4 Aug 2026.